Lymphogranuloma	Lymphogranuloma	NN	B-NP	O		0	15
venereum	venereum	NN	I-NP	O		16	24
presenting	present	VBG	B-VP	O		25	35
as	as	IN	B-SBAR	O		36	38
perianal	perianal	JJ	B-NP	O		39	47
ulceration	ulceration	NN	I-NP	O		48	58
:	:	:	O	O		58	59
an	an	DT	B-NP	O		60	62
emerging	emerge	VBG	I-NP	O		63	71
clinical	clinical	JJ	I-NP	O		72	80
presentation	presentation	NN	I-NP	O		81	93
?	?	.	O	O		93	94

An	An	DT	B-NP	O		95	97
outbreak	outbreak	NN	I-NP	O		98	106
of	of	IN	B-PP	O		107	109
lymphogranuloma	lymphogranuloma	NN	B-NP	O		110	125
venereum	venereum	NN	I-NP	O		126	134
(	(	(	O	O		135	136
LGV	LGV	NN	B-NP	O		136	139
)	)	)	O	O		139	140
infection	infection	NN	B-NP	O		141	150
has	have	VBZ	B-VP	O		151	154
been	be	VBN	I-VP	O		155	159
recognised	recognise	VBN	I-VP	O		160	170
in	in	IN	B-PP	O		171	173
the	the	DT	B-NP	O		174	177
UK	UK	NN	I-NP	O		178	180
since	since	IN	B-PP	O		181	186
2004	2004	CD	B-NP	O		187	191
,	,	,	O	O		191	192
predominantly	predominantly	RB	B-VP	O		193	206
affecting	affect	VBG	I-VP	O		207	216
HIV	HIV	NN	B-NP	O		217	220
-	-	HYPH	I-NP	O		220	221
positive	positive	JJ	I-NP	O		221	229
men	man	NNS	I-NP	O		230	233
who	who	WP	B-NP	O		234	237
have	have	VBP	B-VP	O		238	242
sex	sex	NN	B-NP	O		243	246
with	with	IN	B-PP	O		247	251
men	man	NNS	B-NP	O		252	255
(	(	(	O	O		256	257
MSM	MSM	NN	B-NP	B-protein		257	260
)	)	)	O	O		260	261
.	.	.	O	O		261	262

Patients	Patient	NNS	B-NP	O		263	271
typically	typically	RB	B-ADVP	O		272	281
present	present	VBP	B-VP	O		282	289
with	with	IN	B-PP	O		290	294
proctitis	proctitis	NN	B-NP	O		295	304
symptoms	symptom	NNS	I-NP	O		305	313
.	.	.	O	O		313	314

The	The	DT	B-NP	O		315	318
prevalence	prevalence	NN	I-NP	O		319	329
of	of	IN	B-PP	O		330	332
rectal	rectal	JJ	B-NP	O		333	339
LGV	LGV	NN	I-NP	O		340	343
in	in	IN	B-PP	O		344	346
MSM	MSM	NN	B-NP	O		347	350
attending	attend	VBG	B-VP	O		351	360
sexually	sexually	RB	B-NP	O		361	369
transmitted	transmit	VBN	I-NP	O		370	381
infection	infection	NN	I-NP	O		382	391
clinics	clinic	NNS	I-NP	O		392	399
in	in	IN	B-PP	O		400	402
London	London	NNP	B-NP	O		403	409
is	be	VBZ	B-VP	O		410	412
estimated	estimate	VBN	I-VP	O		413	422
at	at	IN	B-PP	O		423	425
1%	1%	NN	B-NP	O		426	428
.	.	.	O	O		428	429

Health	Health	NNP	B-NP	O		430	436
Protection	Protection	NNP	I-NP	O		437	447
Agency	Agency	NNP	I-NP	O		448	454
surveillance	surveillance	NN	I-NP	O		455	467
has	have	VBZ	B-VP	O		468	471
shown	show	VBN	I-VP	O		472	477
a	a	DT	B-NP	O		478	479
decrease	decrease	NN	I-NP	O		480	488
in	in	IN	B-PP	O		489	491
anorectal	anorectal	JJ	B-NP	O		492	501
manifestations	manifestation	NNS	I-NP	O		502	516
despite	despite	IN	B-PP	O		517	524
little	little	JJ	B-NP	O		525	531
demographic	demographic	JJ	I-NP	O		532	543
change	change	NN	I-NP	O		544	550
.	.	.	O	O		550	551

Two	Two	CD	B-NP	O		552	555
cases	case	NNS	I-NP	O		556	561
of	of	IN	B-PP	O		562	564
HIV	HIV	NN	B-NP	O		565	568
-	-	HYPH	B-NP	O		568	569
infected	infect	VBN	I-NP	O		569	577
patients	patient	NNS	I-NP	O		578	586
presenting	present	VBG	B-VP	O		587	597
with	with	IN	B-PP	O		598	602
isolated	isolate	VBN	B-NP	O		603	611
perianal	perianal	JJ	I-NP	O		612	620
ulcer	ulcer	NN	I-NP	O		621	626
disease	disease	NN	I-NP	O		627	634
are	be	VBP	B-VP	O		635	638
reported	report	VBN	I-VP	O		639	647
here	here	RB	B-ADVP	O		648	652
.	.	.	O	O		652	653

Both	Both	DT	B-NP	O		654	658
cases	case	NNS	I-NP	O		659	664
were	be	VBD	B-VP	O		665	669
confirmed	confirm	VBN	I-VP	O		670	679
to	to	TO	I-VP	O		680	682
have	have	VB	I-VP	O		683	687
rectal	rectal	JJ	B-NP	O		688	694
Chlamydia trachomatis	Chlamydia_trachomatis	NN	I-NP	O		695	716
-	-	HYPH	B-NP	O		716	717
specific	specific	JJ	I-NP	O		717	725
DNA	DNA	NN	I-NP	O		726	729
of	of	IN	B-PP	O		730	732
an	an	DT	B-NP	O		733	735
LGV	LGV	NN	I-NP	B-protein		736	739
associated	associated	JJ	I-NP	I-protein		740	750
serovar	serovar	NN	I-NP	I-protein		751	758
.	.	.	O	O		758	759

As	As	IN	B-SBAR	O		760	762
presentations	presentation	NNS	B-NP	O		763	776
of	of	IN	B-PP	O		777	779
LGV	LGV	NN	B-NP	B-protein		780	783
diversify	diversify	VBP	B-VP	O		784	793
,	,	,	O	O		793	794
further	further	JJ	B-NP	O		795	802
education	education	NN	I-NP	O		803	812
and	and	CC	I-NP	O		813	816
surveillance	surveillance	NN	I-NP	O		817	829
are	be	VBP	B-VP	O		830	833
needed	need	VBN	I-VP	O		834	840
in	in	IN	B-SBAR	O		841	843
order	order	NN	O	O		844	849
to	to	TO	B-VP	O		850	852
reduce	reduce	VB	I-VP	O		853	859
transmission	transmission	NN	B-NP	O		860	872
and	and	CC	O	O		873	876
prevent	prevent	VBP	B-VP	O		877	884
long	long	JJ	B-NP	O		885	889
-	-	HYPH	I-NP	O		889	890
term	term	NN	I-NP	O		890	894
complications	complication	NNS	I-NP	O		895	908
.	.	.	O	O		908	909

A	A	DT	B-NP	O		910	911
strong	strong	JJ	I-NP	O		912	918
argument	argument	NN	I-NP	O		919	927
already	already	RB	B-ADVP	O		928	935
exists	exist	VBZ	B-VP	O		936	942
for	for	IN	B-PP	O		943	946
the	the	DT	B-NP	O		947	950
incorporation	incorporation	NN	I-NP	O		951	964
of	of	IN	B-PP	O		965	967
chlamydia	chlamydia	NN	B-NP	O		968	977
nucleic	nucleic	JJ	I-NP	O		978	985
acid	acid	NN	I-NP	O		986	990
amplification	amplification	NN	I-NP	O		991	1004
tests	test	NNS	I-NP	O		1005	1010
in	in	IN	B-PP	O		1011	1013
the	the	DT	B-NP	O		1014	1017
management	management	NN	I-NP	O		1018	1028
of	of	IN	B-PP	O		1029	1031
MSM	MSM	NN	B-NP	B-protein		1032	1035
with	with	IN	B-PP	O		1036	1040
proctitis	proctitis	NN	B-NP	O		1041	1050
;	;	:	O	O		1050	1051
this	this	DT	B-NP	O		1052	1056
paper	paper	NN	I-NP	O		1057	1062
provides	provide	VBZ	B-VP	O		1063	1071
evidence	evidence	NN	B-NP	O		1072	1080
that	that	IN	B-SBAR	O		1081	1085
this	this	DT	B-NP	O		1086	1090
should	should	MD	B-VP	O		1091	1097
be	be	VB	I-VP	O		1098	1100
extended	extend	VBN	I-VP	O		1101	1109
to	to	TO	B-PP	O		1110	1112
MSM	MSM	NN	B-NP	B-protein		1113	1116
with	with	IN	B-PP	O		1117	1121
perianal	perianal	JJ	B-NP	O		1122	1130
ulcer	ulcer	NN	I-NP	O		1131	1136
disease	disease	NN	I-NP	O		1137	1144
.	.	.	O	O		1144	1145

